吉非替尼治疗表皮生长因子受体突变型非小细胞肺癌患者的效果及影响因素分析  

Efficacy and influencing factors of gefitinib in the treatment of epidermal growth factor receptor mutant non-small cell lung cancer

作　　者：吕秀霞 刘赛赛 乔通 李黎明 刘青锋 LYU Xiuxia;LIU Saisai;QIAO Tong;LI Liming;LIU Qingfeng(Department of Nursing,He’nan Provincial People’s Hospital/People’s Hospital of Zhengzhou University,Zhengzhou 450003,He’nan,China;Chest Tumor Diagnosis and Treatment Center,He’nan Provincial People’s Hospital/People’s Hospital of Zhengzhou University,Zhengzhou 450003,He’nan,China;Department of Thoracic Surgery,He’nan Provincial People’s Hospital/People’s Hospital of Zhengzhou University,Zhengzhou 450003,He’nan,China)

机构地区：[1]河南省人民医院,郑州大学人民医院护理部,郑州450003 [2]河南省人民医院,郑州大学人民医院胸部肿瘤诊疗中心,郑州450003 [3]河南省人民医院,郑州大学人民医院胸外科,郑州450003

出　　处：《癌症进展》2021年第17期1763-1765,1777,共4页Oncology Progress

基　　金：2019年度河南省医学科技公关计划省部共建项目(SB201901080)。

摘　　要：目的观察吉非替尼治疗表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)患者的疗效并探讨影响因素。方法选取150例EGFR突变型NSCLC患者的临床资料,所有患者均给予吉非替尼口服治疗,连续治疗6个疗程,评估其临床疗效,并对可能影响EGFR突变型NSCLC患者临床疗效的相关因素进行单因素和多因素分析。结果150例患者中,总缓解患者48例(32.00%)设为缓解组,剩余102例患者设为对照组。缓解组和对照组患者性别、肿瘤分期、病理类型和肿瘤直径比较,差异均有统计学意义(P﹤0.05)。Logistic回归分析结果显示,性别、肿瘤分期、病理类型和肿瘤直径均为EGFR突变型NSCLC患者临床疗效的影响因素(P﹤0.05)。治疗期间,150例患者药物不良反应总发生率为28.67%。结论吉非替尼治疗EGFR突变型NSCLC患者有一定的临床疗效,性别、肿瘤分期、病理类型和肿瘤直径均为EGFR突变型NSCLC患者临床疗效的影响因素。Objective To observe the efficacy of Gefitinib in the treatment of epidermal growth factor receptor(EG-FR)mutant non-small cell lung cancer(NSCLC)and the influencing factors.Method Clinical data of 150 patients with EGFR mutant NSCLC were selected.All patients were treated orally with Gefitinib for 6 consecutive courses to evaluate the clinical efficacy,and the univariate and multivariate analysis were conducted to analyze the related factors influencing the clinical efficacy of EGFR mutant NSCLC patients.Result There were 48(32.00%)response cases enrolled into the response group,and remaining 102 cases into the control group among 150 patients.There were significant differences in gender,tumor stage,pathological type and tumor diameter between the two groups(P<0.05).Logistic regression showed that gender,tumor stage,pathological type and tumor diameter were all related factors influencing the clinical outcome of EGFR mutant NSCLC patients(P<0.05).During the treatment,the total incidence of drug toxicity in 150 patients was 28.67%.Conclusion Gefitinib have a certain clinical efficacy in the treatment of EGFR mutant NSCLC patients.The gender,tumor stage,pathological type and tumor diameter may affect the clinical efficacy of Gefitinib tablets in the treat-ment of EGFR mutant NSCLC patients.

关 键 词：吉非替尼 表皮生长因子受体突变 非小细胞肺癌 疗效 影响因素 

分 类 号：R734.2[医药卫生—肿瘤]